As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid development of lifesaving covid shots.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...

在大西洋彼岸取得的一项重大法律胜利是推动Moderna（MRNA）股票在周三大幅上涨的动力。这家以生产Spikevax新冠疫苗而闻名的公司的胜利，使股票在交易时段内上涨了近16%。相比之下，标普500指数仅上涨1.1%。

Highly pathogenic avian influenza continues to devastate poultry flocks throughout the United States, as well as cause ...

The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that ...